NasdaqGM - Nasdaq Real Time Price USD

Wave Life Sciences, Inc. (WVE)

4.9000 -0.1400 (-2.78%)
At close: August 31 at 4:00:00 PM EDT
4.8500 -0.0500 (-1.02%)
Pre-Market: 6:37:32 AM EDT
Trade WVE on Coinbase
Chart Range Bar
Loading chart for WVE
  • Previous Close 5.0400
  • Open 5.0300
  • Bid 4.2700 x 200
  • Ask 7.5000 x 200
  • Day's Range 4.8400 - 5.0700
  • 52 Week Range 4.8400 - 21.7300
  • Volume 3,811,047
  • Avg. Volume 3,080,212
  • Market Cap (intraday) 965.536M
  • Beta (5Y Monthly) -1.29
  • PE Ratio (TTM) --
  • EPS (TTM) -1.0800
  • Earnings Date Nov 9, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 19.06

Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.

wavelifesciences.com

317

Full Time Employees

December 31

Fiscal Year Ends

Performance Overview

Trailing total returns as of 8/31/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

WVE
71.18%
S&P 500 (^GSPC)
12.28%

1-Year Return

WVE
48.96%
S&P 500 (^GSPC)
18.98%

3-Year Return

WVE
12.64%
S&P 500 (^GSPC)
70.51%

5-Year Return

WVE
22.59%
S&P 500 (^GSPC)
69.95%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized
 

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 2.27M
Earnings -69.36M
Profit Margin -3,052.60%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-60M
-40M
-20M
0
20M
-3000.0%
-2000.0%
-1000.0%
 

Analyst Insights

View More

Analyst Price Targets

12.00
19.06 Average
4.9000 Current
42.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Latest Rating

Date 8/4/2026
Analyst Mizuho
Rating Action Maintains
Rating Outperform
Price Action Lowers
Price Target 27 -> 23
 

Statistics

View More

Valuation Measures

Annual
As of 8/27/2026
  • Market Cap

    1.02B

  • Enterprise Value

    569.76M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    14.84

  • Price/Book (mrq)

    2.24

  • Enterprise Value/Revenue

    8.72

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -33.60%

  • Return on Equity (ttm)

    -67.42%

  • Revenue (ttm)

    65.37M

  • Net Income Avi to Common (ttm)

    -202.47M

  • Diluted EPS (ttm)

    -1.0800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    490.6M

  • Total Debt/Equity (mrq)

    9.61%

  • Levered Free Cash Flow (ttm)

    -128.78M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

4.9000 Current
 

Dividend Score

0 Low
Sector Avg.
100 High
 

Hiring Score

0 Low
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
Sector Avg.
100 High
 

People Also Watch